Article ; Online: SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Expert opinion on therapeutic patents
2020 Volume 30, Issue 8, Page(s) 567–579
Abstract: ... by SARS-CoV-1, MERS-CoV, and currently SARS-CoV-2 (COVID-19), the causative agent of coronavirus disease ... for SARS-CoV-1, SARS-CoV-2 and MERS-CoV.: Areas covered: To treat SARS, MERS and SARS-CoV-2, researchers ... can serve as an aid in the new pandemic by SARS-CoV-2 and be a starting point for new treatments ...
| Abstract | Introduction: Coronavirus has been responsible for several virus outbreaks since 2003, caused by SARS-CoV-1, MERS-CoV, and currently SARS-CoV-2 (COVID-19), the causative agent of coronavirus disease in 2019. COVID-19 has become a global public health emergency because of its high virulence and mortality capacity. This patent review aims to provide an overview of the patents that present possible treatments for SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Areas covered: To treat SARS, MERS and SARS-CoV-2, researchers have filed patents for a number of therapeutic agents. Most of the treatments found were protease inhibitors aimed at proteases such as PLpro, 3 CLpro, RNA helicase, and Spike protein, or used monoclonal antibodies and interferons. In addition, the use of Chinese folk medicine and its multitude of medicinal plants with strong antiviral properties was reinforced. Thus, these therapies used in previous epidemics can serve as an aid in the new pandemic by SARS-CoV-2 and be a starting point for new treatments. Expert opinion: The various antiviral alternatives presented in this review offer therapeutic options to fight coronavirus infections. If shown to be effective, these drugs may be extremely important in the current pandemic. |
|---|---|
| MeSH term(s) | Animals ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; Betacoronavirus/drug effects ; Betacoronavirus/pathogenicity ; COVID-19 ; Coronavirus Infections/diagnosis ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Drug Development ; Drug Discovery ; Host-Pathogen Interactions ; Humans ; Middle East Respiratory Syndrome Coronavirus/drug effects ; Middle East Respiratory Syndrome Coronavirus/pathogenicity ; Pandemics ; Patents as Topic ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; SARS Virus/drug effects ; SARS Virus/pathogenicity ; SARS-CoV-2 ; Severe Acute Respiratory Syndrome/diagnosis ; Severe Acute Respiratory Syndrome/drug therapy ; Severe Acute Respiratory Syndrome/virology ; Treatment Outcome |
| Chemical Substances | Antiviral Agents |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-06-07 |
| Publishing country | England |
| Document type | Journal Article ; Review |
| ZDB-ID | 1186201-4 |
| ISSN | 1744-7674 ; 0962-2594 ; 1354-3776 |
| ISSN (online) | 1744-7674 |
| ISSN | 0962-2594 ; 1354-3776 |
| DOI | 10.1080/13543776.2020.1772231 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 3962: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.